Phenotypes associated with this allele

• Allele Symbol: Fev^tm2Esd
• Allele Name: targeted mutation 2, Evan S Deneris
• Allele ID: MGI:4837197
• Summary: 3 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Fev^tm1Esd/Fev^tm2Esd Tg(Fev-cre/ERT2)aEsd/0	involves: 129S1/Sv * 129X1/SvJ * C57BL/6	MGI:4837216
cn2	Fev^tm1Esd/Fev^tm2Esd Tg(Fev-cre)1Esd/0	involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL	MGI:4837211
cn3	Fev^tm1Esd/Fev^tm2Esd Gt(ROSA)26Sor^tm1(EYFP)Cos/Gt(ROSA)26Sor^+ Tg(Fev-cre)1Esd/0	involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL	MGI:4837213

Genotype
MGI:4837216

cn1

• Allelic Composition: Fev^tm1Esd/Fev^tm2Esd; Tg(Fev-cre/ERT2)aEsd/0
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

behavior/neurological

increased anxiety-related response ( J:165266 )

• following 4 weeks of tamoxifen treatment started at 6-8 weeks of age, mice spend less time and make fewer entrances into the open arms of an elevated plus maze

• however, the level of exploratory behavior in the elevated plus maze is normal

• following 4 weeks of tamoxifen treatment started at 6-8 weeks of age, mice spend more time in the dark chamber in a light dark exploration assay

increased thigmotaxis ( J:165266 )

• following 4 weeks of tamoxifen treatment started at 6-8 weeks of age, mice spend less time in the center of an open field

homeostasis/metabolism

decreased serotonin level ( J:165266 )

• following 4 weeks of tamoxifen treatment started at 6-8 weeks of age, brain levels of 5-HT and 5-HIAA are significantly decreased

Genotype
MGI:4837211

cn2

• Allelic Composition: Fev^tm1Esd/Fev^tm2Esd; Tg(Fev-cre)1Esd/0
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL

nervous system

nervous system phenotype ( J:165266 )

N • unlike germline null mice, the number of serotonergic neurons is normal at E11.5 and E12.5

Genotype
MGI:4837213

cn3

• Allelic Composition: Fev^tm1Esd/Fev^tm2Esd; Gt(ROSA)26Sor^tm1(EYFP)Cos/Gt(ROSA)26Sor⁺; Tg(Fev-cre)1Esd/0
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL

nervous system

abnormal somatosensory cortex morphology ( J:165266 )

• serotonergic innervation of the somatosensory cortex from dorsal raphe nucleus 5-HT neurons is significantly disrupted

abnormal innervation ( J:165266 )

• serotonergic innervation of the somatosensory cortex from dorsal raphe nucleus 5-HT neurons is significantly disrupted

abnormal serotonergic neuron morphology ( J:165266 )

• serotonergic innervation of the somatosensory cortex from dorsal raphe nucleus 5-HT neurons is significantly disrupted

abnormal nervous system electrophysiology ( J:165266 )

• neither high nor low concentrations of 8-Hydroxy-2-dipropylaminotetralin hydrobromide (8-OH-DPAT) elicit a change in baseline currents in labeled 5HT neurons

abnormal action potential ( J:165266 )

• YFP+ cells show increased spontaneous firing of action potentials